ReviewJournal of the Endocrine Society2022

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women.

Jacob E Pruett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.